Daxor Corp. DXR
Medical/Dental Instruments · data as of November 13, 2026
Daxor Corp. (DXR) is a healthcare company listed in the US with a market value of about $50M. In fiscal year 2011 it had revenue of $1M and net income of -$7M, a net margin of -496.8%.
Its overall Stock Analiz score is 1.0 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -11%.
About Daxor
Daxor is listed in the US and classified in medical/dental instruments. It was profitable in 1 of the last 2 years in our data. It spends 187% of revenue on research and development.
Score: 1.0 / 5
Checks passed
- Strong R&D investment or growth above 20%
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
- Pays a dividend
- Stock-based pay below 5% of revenue
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 2 years
| Fiscal year | 2011 | 2010 |
|---|---|---|
| Revenue | $1M | — |
| Net income | -$7M | $5M |
| Free cash flow | -$7M | -$6M |
| EPS (diluted) | $-1.70 | $1.17 |
| Net margin | -496.8% | — |
| ROIC | -12.5% | -9.4% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Does Daxor pay a dividend?
Yes. The dividend yield is about 2.13%, and it has paid dividends for 2 years in our data.
Is Daxor a good stock to buy?
We do not give buy or sell advice. Daxor scores 1.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.